Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191
Debt
Debt-to-Equity Ratio0.95
Current Ratio6.84
Quick Ratio6.84
Price-To-Earnings
Trailing P/E Ratio-0.33
Forward P/E Ratio-1.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$230,000.00
Price / Sales243.09
Cash FlowN/A
Price / CashN/A
Book Value($0.21) per share
Price / Book-3.07
Profitability
EPS (Most Recent Fiscal Year)($1.98)
Net Income$-56,710,000.00
Net MarginsN/A
Return on Equity-780.98%
Return on Assets-127.47%
Miscellaneous
Employees52
Outstanding Shares86,630,000
Market Cap$51.11 million
Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences Inc (NASDAQ:GNCA) issued its earnings results on Friday, August, 10th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.08. View Genocea Biosciences' Earnings History.
When is Genocea Biosciences' next earnings date?
What price target have analysts set for GNCA?
7 equities research analysts have issued 1-year target prices for Genocea Biosciences' stock. Their forecasts range from $2.50 to $10.00. On average, they anticipate Genocea Biosciences' share price to reach $4.7857 in the next twelve months. This suggests a possible upside of 641.5% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.
What is the consensus analysts' recommendation for Genocea Biosciences?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.
What are Wall Street analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (7/11/2018)
- 2. Cantor Fitzgerald analysts commented, "GNCA shares could experience some weakness on the news of the departure of the CFO, Jonathan Poole, who resigned effective 3/23, to pursue other opportunities." (3/11/2018)
Are investors shorting Genocea Biosciences?
Genocea Biosciences saw a drop in short interest in July. As of July 13th, there was short interest totalling 1,853,951 shares, a drop of 22.4% from the June 29th total of 2,389,426 shares. Based on an average daily trading volume, of 327,593 shares, the days-to-cover ratio is presently 5.7 days. Approximately 3.8% of the shares of the company are short sold. View Genocea Biosciences' Current Options Chain.
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include Fennec Pharmaceuticals (FENC), Idera Pharmaceuticals (IDRA), Krystal Biotech (KRYS), Compugen (CGEN), Pluristem Therapeutics (PSTI), Organovo (ONVO), Cidara Therapeutics (CDTX), Eiger Biopharmaceuticals (EIGR), Aptose Biosciences (APTO), Champions Oncology (CSBR), Brainstorm Cell Therapeutics (BCLI), Applied Genetic Technologies (AGTC), Entera Bio (ENTX), Aevi Genomic Medicine (GNMX) and Curis (CRIS).
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 49)
- Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 73)
- Dr. Darren Higgins Ph.D., Scientific Co-Founder and Member of Scientific Advisory Board
- Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 46)
- Mr. Eric S. Hoffman, Chief Bus. Officer (Age 48)
Has Genocea Biosciences been receiving favorable news coverage?
Media headlines about GNCA stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Genocea Biosciences earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.50 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Genocea Biosciences.
Who are Genocea Biosciences' major shareholders?
Genocea Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.99%), Paloma Partners Management Co (0.46%), BlackRock Inc. (0.28%), DRW Securities LLC (0.28%) and LMR Partners LLP (0.24%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.
Which institutional investors are selling Genocea Biosciences stock?
Which institutional investors are buying Genocea Biosciences stock?
GNCA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Paloma Partners Management Co, DRW Securities LLC and LMR Partners LLP. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.
How do I buy shares of Genocea Biosciences?
Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of GNCA stock can currently be purchased for approximately $0.6454.
How big of a company is Genocea Biosciences?
Genocea Biosciences has a market capitalization of $51.11 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-56,710,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Genocea Biosciences employs 52 workers across the globe.
How can I contact Genocea Biosciences?
Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
